Fungal infections are now becoming a hazard to individuals which has paved the way for
research to expand the therapeutic options available. Recent advances in drug design and …

There have been many new developments in antifungal therapy in the past few years. Some
antifungal drugs have been reformulated to reduce toxicity (eg new lipid formulations of …

Fungal infections are a universal problem and are routinely associated with high morbidity
and mortality rates in immunocompromised patients. Existing therapies comprise five …

Fungal infections are a major public health problem resulting from the lack of public policies
addressing these diseases, toxic and/or expensive therapeutic tools, scarce diagnostic tests …

Fungi are eukaryotic, single cell or multicellular organisms which cause a wide range of
human diseases ranging from superficial skin to invasive life-threatening infections. Over the …

Fungi are simple eukaryotic organisms that have colonized diverse environments around
the planet. There are approximately 2 million different species of fungi on the Earth [1]. Their …

There is a need for new antifungal agents, mainly due to increased incidence of invasive
fungal infections (IFI), high frequency of associated morbidity and mortality and limitations of …

An increasing clinical burden of fungal disease is associated with chronic (eg chronic
pulmonary aspergillosis), systemic (eg candidemia and cryptococcal meningoencephalitis) …

Highlights•There is a dire need for novel antifungal therapies.•Recent clinical trials of directly
repurposed drugs have failed.•The most recently approved antifungals underwent …

Introduction: Invasive fungal infection carries a high morbidity, mortality and economic cost.
In recent times, a rising incidence of fungal infection and antifungal resistance is occurring …